Results 211 to 220 of about 43,675 (258)

Biological Evaluation of a Novel Compound with Predicted EZH2 and EED Binding Against Human Malignant Melanoma Cells. [PDF]

Int J Mol Sci
Gorbunov S, Kyriakou S, Anestopoulos I, Khoso S, Manfredi M, Franco R, Pappa A, Panayiotidis MI.   +7 more
europepmc   +1 more source

Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity. [PDF]

J Clin Invest
Yang Y, Zhang X, Venkadakrishnan VB, Zou H, Zheng X, Guo S, Chen CZ, Borowsky AD, Corey E, Evans RM, Gao AC, Dall'Era MA, Zoubeidi A, Lara PN, Kung HJ, Chen X, Beltran H, Chen HW.   +17 more
europepmc   +1 more source

Identification of a Novel PDRG1-EZH2-p21 Pathway Controlling Senescence and Tumor Progression in Hepatocellular Carcinoma. [PDF]

Int J Biol Sci
Yang Q, Zhang L, Li W, Zhang Z, Tao J, Rong Y, Wang W.   +6 more
europepmc   +1 more source

The noncanonical role of EZH2 in cancer [PDF]

Cancer Science, 2021
AbstractEnhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2). Dysregulation of EZH2 causes alteration of gene expression and functions, thereby promoting cancer development. The regulatory function of EZH2 varies across different tumor types.
Zhigang Jin, , Tiejun Zhao
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

Nature, 2012
In eukaryotes, post-translational modification of histones is critical for regulation of chromatin structure and gene expression. EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2) and is involved in repressing gene expression through methylation of histone H3 on lysine 27 (H3K27).
Michael T, McCabe, Heidi M, Ott, Gopinath, Ganji, Susan, Korenchuk, Christine, Thompson, Glenn S, Van Aller, Yan, Liu, Alan P, Graves, Anthony, Della Pietra, Elsie, Diaz, Louis V, LaFrance, Mark, Mellinger, Celine, Duquenne, Xinrong, Tian, Ryan G, Kruger, Charles F, McHugh, Martin, Brandt, William H, Miller, Dashyant, Dhanak, Sharad K, Verma, Peter J, Tummino, Caretha L, Creasy   +21 more
openaire   +2 more sources

EZH2 Inhibitors: The Unpacking Revolution

Cancer Research, 2022
Abstract The methylation of lysine 27 on histone H3 (H3K27me3) is a chromatin mark associated with nucleosome condensation and gene expression silencing. EZH2 is a lysine methyltransferase that catalyzes H3K27me3. In this issue of Cancer Research, Porazzi and colleagues report that pretreatment with EZH2 inhibitors opened up the H3K27me3-
Vera, Adema, Simona, Colla
openaire   +2 more sources

The role of EZH2 in tumour progression [PDF]

British Journal of Cancer, 2011
Accumulated evidence shows that EZH2 is deregulated in a wide range of cancer types, and it has a crucial role in stem cell maintenance and tumour development. Therefore, blocking EZH2 expression or activity may represent a promising strategy for anticancer treatment.
Mien-Chie Hung, Hung M-C
exaly   +3 more sources

Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader

Oncogene, 2023
Multiple myeloma (MM) is the second most common hematological malignancy with poor prognosis. Enhancer of zeste homolog 2 (EZH2) is the enzymatic subunit of polycomb repressive complex 2 (PRC2), which catalyzes trimethylation of histone H3 lysine 27 (H3K27me3) for transcriptional repression.
Xufen Yu, Jun Wang, Weida Gong, Anqi Ma, Yudao Shen, Chengwei Zhang, Xijuan Liu, Ling Cai, Jing Liu, Gang Greg Wang, Jian Jin   +10 more
openaire   +2 more sources